Levetiracetam Zentiva (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates calcium‑dependent exocytosis, stabilising synaptic activity and reducing the neuronal hyperexcitability that triggers epileptic seizures.

The dosage of Levetiracetam Zentiva is individualized. A qualified prescriber determines the appropriate dose based on the patient’s age, renal function, seizure type, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Data on levetiracetam use in pregnancy and lactation are limited. Clinicians weigh potential benefits against unknown risks before prescribing to pregnant or nursing women. If treatment is necessary, close monitoring and consultation with a specialist are recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable drug‑interaction profile. It is often chosen for patients who need a medication with fewer enzyme‑inducing effects, though individual response and tolerability vary.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. No special refrigeration is required for this oral formulation.

Levetiracetam Zentiva is taken orally, with or without food, as directed by the prescriber. Tablets should be swallowed whole with water. The exact timing and frequency depend on the individualized dosing schedule established by the treating physician.

Serious adverse events include severe allergic reactions (rash, swelling, breathing difficulty), psychiatric disturbances such as new‑onset depression, suicidal thoughts, or psychosis, and hematologic abnormalities like unexplained bruising or low blood counts. Prompt medical attention is required if any of these occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications that markedly reduce its plasma levels.